Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development.

Autor:	Dawood HN; Al Immamin al kadhimin Medical City, Baghdad, 10011, Iraq., Al-Jumaili AH; Merit consultant pediatrician, Baghdad, 10011, Iraq., Radhi AH; F.i.c.m.s/ C.M, Center for disease control and prevention, Baghdad, Iraq., Ikram D; Pfizer, Baghdad, Iraq., Al-Jabban A; Pfizer, Baghdad, Iraq.
Jazyk:	angličtina
Zdroj:	F1000Research [F1000Res] 2023 Dec 28; Vol. 12, pp. 435. Date of Electronic Publication: 2023 Dec 28 (Print Publication: 2023).
DOI:	10.12688/f1000research.132781.2
Abstrakt:	Pneumococcal disease is a global public health concern as it affects the young, aged and the immunocompromised. The development of pneumococcal vaccines and their incorporation in the immunization programs has helped to reduce the global burden of disease. However, serotype replacement and the emergence of non-vaccine serotypes as well as the persistence of a few vaccine serotypes underscores the need for development of new and effective vaccines against such pneumococcal serotypes. In the Middle East, places of religious mass gatherings are a hotspot for disease transmission in addition to the global risk factors. Therefore, the periodic surveillance of pneumococcal serotypes circulating in the region to determine the effectiveness of existing prevention strategies and develop improved vaccines is warranted. Currently, there is a lack of serotype prevalence data for Iraq due to inadequate surveillance in the region. Thus, this review aims to determine the pneumococcal serotypes circulating in Iraq which may help in the development and introduction of improved pneumococcal vaccines in the country. Competing Interests: Competing interests: Delan Ikram and Ali Al-Jabban are Pfizer employees. (Copyright: © 2023 Dawood HN et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu